Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Signal Transduction And Targeted Therapy (IF=38.104). The title of the study is "Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma". This study sheds light on the promising potential of FCRL5-directed CAR-T cell therapy in the treatment of multiple myeloma (MM).
Annual Review | Professor Hui Wei: Progress in Clinical Diagnosis and Treatment of Acute Myeloid Leukemia (AML)

Annual Review | Professor Hui Wei: Progress in Clinical Diagnosis and Treatment of Acute Myeloid Leukemia (AML)

With ardent vigor and unwavering dedication, the past year has seen significant advances in the field of hematologic oncology, driven by the rapid development of innovative therapies and cutting-edge technologies. The application of novel molecular biology techniques has not only refined the prognostic stratification of Acute Myeloid Leukemia (AML) but has also fostered more precise diagnostics and treatments. At the turn of the year, Oncology Frontier - Hematology Frontier has invited Professor Hui Wei, Director of the Leukemia Diagnosis and Treatment Center at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, to review the latest advancements in the precise diagnosis and treatment of AML in 2023, and to look forward to the future prospects and directions of AML treatment.